Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Abstract
Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 14, 2018
- Source ID
- 10.1158/1078-0432.ccr-17-1327
Entities
People
- Barbara M. Norquist
- Cheryl Bailey
- Elizabeth M Swisher
- Floor Backes
- Gretchen Glaser
- Heather A. Lankes
- John Soper
- Krishnansu S. Tewari
- Maria I. Harrell
- Mark F. Brady
- Mary Claire King
- Michael J. Birrer
- Ming K. Lee
- Nilsa C. Ramirez
- Robert A. Burger
- Robert S. Mannel
- Sarah S. Bernards
- Silvia Casadei
- Stephen Rubin
- Suleyman Gulsuner
- Tom Walsh
Organizations
- Fox Chase Cancer Center
- Mayo Clinic
- National Cancer Institute
- Ohio State University
- Ovarian Cancer Research Alliance
- The Research Institute at Nationwide Children's Hospital
- United States Department of Defense
- University of Alabama
- University of California, Irvine
- University of North Carolina
- University of Oklahoma
- University of Pennsylvania
- University of Washington
- V Foundation for Cancer Research